Recital 12, Regulation (EU) 2024/3169

In forcesince 18 Dec 2024

To reduce administrative burden and avoid duplication, where joint scientific consultations on medicinal products are conducted in parallel with the scientific advice, the health technology developer should submit the same documentation to the HTA secretariat and to the European Medicines Agency. For this purpose, before establishing the template of the briefing package pursuant to Article 21, point (b), of Regulation (EU) 2021/2282 to be used where the joint scientific consultation on medicinal products is carried out in parallel with the scientific advice, the Coordination Group should consult and reach agreement with the European Medicines Agency on the template.